Charles A Powell, MD
- DIRECTOR, MOUNT SINAI-NATIONAL JEWISH HEALTH RESPIRATORY INSTITUTE
- PROFESSOR | Medicine, Pulmonary, Critical Care and Sleep Medicine
Specialties:Pulmonary Medicine, Critical Care Medicine
Charles Powell, MD, is a Professor Medicine and Chief of the Division of Pulmonary, Critical Care and Sleep Medicine. He is also the CEO of the Mount Sinai-National Jewish Health Respiratory Institute.
Dr. Powell completed his medical degree at University of Chicago Pritzker School of Medicine, his residency at Columbia Presbyterian Medical Center, and his clinical and research fellowships at Boston University School of Medicine. With clinical and research interests in lung cancer and mesothelioma, Dr. Powell’s investigations center on understanding the genetic and susceptibility factors for these diseases, and the molecular events that are important in the early stages of lung cancer development and progression. His numerous articles and abstracts have been published in journals such as the American Journal of Respiratory and Critical Care Medicine, American Journal of Pathology, CHEST, Cancer, and the American Journal of Respiratory Cell and Molecular Biology. He is Chair of the Thoracic Oncology Section of the American Thoracic Society, an elected member of the Fleischner Society, and a recipient of the American Cancer Society Research Scholar Award.
IN THE NEWS: Dr. Powell discusses the risk factors for lung cancer in the The Daily News feature, The Daily Checkup.
Critical Care Medicine
American Board of Internal Medicine
- Bronchoscopy, Diagnostic
- Lung Cancer
MD, University of Chicago
Residency, Internal Medicine, Columbia-Presbyterian Medical Center
Fellowship, Pulmonary & Critical Care, Boston University
Lung adenocarcinoma can progress from an indolent in situ carcinoma to an invasive, aggressive, metastatic tumor. The WHO/IASLC/ATS Lung adenocarcinoma classification emphasizes the distinction of adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma from their invasive counterparts. Molecular biomarkers of invasion can distinguish invasive from non-invasive tumors, a distinction that is typically difficult to make in small biopsies and cytology specimens and is becoming increasingly important as the recognition of early stage adenocarcinoma increases with the widespread implementation of lung cancer screening programs in the United States. Please visit the Charles Powell Lab.